$4.36 Billion is the total value of Bpifrance SA's 8 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Exit | CRISPR THERAPEUTICS AG | $0 | – | -4,800 | -100.0% | -0.02% | – |
| SQNS | Exit | SEQUANS COMMUNICATIONS S Aspons ads | $0 | – | -3,300,018 | -100.0% | -0.44% | – |
| CSTM | Exit | CONSTELLIUM NVcl a | $0 | – | -16,393,903 | -100.0% | -6.90% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bpifrance Participations SA #1
- Bpifrance Investissement SAS #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CRITEO S A | 20 | Q3 2023 | 10.1% |
| TECHNIPFMC PLC | 13 | Q4 2021 | 68.1% |
| STELLANTIS NV | 11 | Q3 2023 | 90.9% |
| CONSTELLIUM NV | 11 | Q2 2021 | 41.6% |
| SEQUANS COMMUNICATIONS S A | 11 | Q2 2021 | 5.8% |
| CELLECTIS S.A. | 10 | Q2 2023 | 2.3% |
| CONSTELLIUM NV | 9 | Q3 2023 | 8.3% |
| SEQUANSCOMMUNICATIONS S A | 9 | Q3 2023 | 0.5% |
| MILLENDO THERAPEUTICS INC | 8 | Q3 2020 | 1.8% |
| VECTIVBIO HOLDING AG | 8 | Q1 2023 | 0.8% |
View Bpifrance SA's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-06 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-11 |
View Bpifrance SA's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.